Resolution Therapeutics partners with the Blood Centers of America, Inc. to support broad patient access to its experimental Regenerative Macrophage Therapy in the U.S.
- Partnership will support Resolution’s pivotal clinical program in 2027, as well as future commercial preparedness for RTX001, its lead asset in patients with end-stage liver disease (ESLD)
- Primary goal is to ensure patients can access treatment in the community setting, where the majority of decompensated patients are managed
- RTX001 has the potential to be the first treatment that demonstrates a clear and durable improvement in transplant free survival for ESLD patients
Edinburgh and London, UK, 1 September 2026 – Resolution Therapeutics Limited (“Resolution” or “Company”), a clinical-stage biopharmaceutical company pioneering Regenerative Macrophage Therapy (RMT) in inflammatory and fibrotic diseases, today announced a partnership with the Blood Centers of America, Inc. (BCA) to ensure broad patient access to its pivotal clinical program for RTX001, its lead asset in end-stage liver disease (decompensated cirrhosis), in the U.S.
